Summary Investigation of genetic changes in tumours by loss of heterozygosity (LOH) is a powerful technique for identifying chromosomal regions that may contain tumour suppressor genes. LOH has been described on chromosome 6 in ovarian carcinoma using restriction fragment length polymorphism analysis with a small number of probes. We studied 29 ovarian carcinomas with 19 probes mapping to chromosome 6. Sixteen of the 29 tumours showed LOH on 6q (55%). Of these 16, 63% showed loss of all informative markers on that arm. One tumour showed loss of 6q24-qter, localising the putative tumour suppressor gene to that region. Loss on 6p was 28% overall. However, using three dinucleotide repeat primer pairs from 6p to study LOH in seven (Friend et al., 1986) , with the finding that a germline mutation constituted the first 'hit', to be followed by a second, somatic inactivation of the gene, which was usually detectable by RFLP analysis of filters of DNA from matched normal-tumour pairs. More recently, it has been shown that some families with retinoblastoma share a common mutation that can be traced from affected parent to affected child. In these cases, the other allele is lost or inactivated in various ways that differ in different affected family members (Phillips et al., 1991).
Summary Investigation of genetic changes in tumours by loss of heterozygosity (LOH) is a powerful technique for identifying chromosomal regions that may contain tumour suppressor genes. LOH has been described on chromosome 6 in ovarian carcinoma using restriction fragment length polymorphism analysis with a small number of probes. We studied 29 ovarian carcinomas with 19 probes mapping to chromosome 6. Sixteen of the 29 tumours showed LOH on 6q (55%). Of these 16, 63% showed loss of all informative markers on that arm. One tumour showed loss of 6q24-qter, localising the putative tumour suppressor gene to that region. Loss on 6p was 28% overall. However, using three dinucleotide repeat primer pairs from 6p to study LOH in seven selected tumours, LOH was demonstrated at both 6p22.3-pter and at 6pl2-6p22. These results confirm that 6q harbours a tumour suppressor gene of relevance to ovarian carcinoma and suggest that there may also be a similar gene(s) on 6p. By Southern analysis, there was no evidence of genomic rearrangements of the oestrogen receptor gene, located at 6q25. 1. LOH on 6q was more common in high than low grade tumours. The relevance of our findings to previous work in ovarian cancer and other solid tumours is discussed.
Despite advances in chemotherapy for solid tumours in the past decade or so, the outlook for those women with advanced ovarian cancer remains dismal. Because of its late presentation, the overall 5 year survival is around 28%, whilst early-stage disease has a much better prognosis (Slevin, 1986) . It (Weinberg, 1991) . The original 'two-hit' hypothesis of Knudson (1971) was first confirmed in retinoblastoma by the cloning of the Rb gene (Friend et al., 1986) , with the finding that a germline mutation constituted the first 'hit', to be followed by a second, somatic inactivation of the gene, which was usually detectable by RFLP analysis of filters of DNA from matched normal-tumour pairs. More recently, it has been shown that some families with retinoblastoma share a common mutation that can be traced from affected parent to affected child. In these cases, the other allele is lost or inactivated in various ways that differ in different affected family members (Phillips et al., 1991) .
For soine years there has been considerable cytogenetic evidence that in OC, one chromosome 6, particularly the long arm, is missing in part or in whole (Mitelman, 1991 (Pejovic et al., 1992 seven had breakpoints between 6q21 -23, thus loss of the long arm telomeric to this region was the commonest single abnormality of chromosome 6 in this study. Despite the common occurrence of aneuploidy, Atkin et al. (1983) showed that one copy of 6q may be lost in early stage tumours, when the karotype is relatively undisturbed. These data have been followed up more recently by molecular studies of LOH that have broadly confirmed the cytogenetic findings (Ehlen & Dubeau, 1990; Lee et al., 1990) .
Further data are now needed to accurately define regions of LOH, so that efforts can be concentrated on cloning genes in the relevant region of chromosome 6. Therefore we have studied 29 pairs of matched malignant tumour and normal DNA with ten DNA markers that detect polymorphic sequences on 6q and six that do so on 6p. We also used the centromeric marker p308 (D6ZJ). Oka et al. (1991) showed that by using carefully dissected tumours it was possible to reliably demonstrate LOH by PCR. Subsequently dinucleotide (microsatellite) repeats mapping to chromosome 17 were used to successfully demonstrate LOH in breast cancer (Futreal et al., 1992) . Therefore we included the dinucleotide repeats D6S89 and FTHPI, which were utilised to study the regions 6p22.3-23 and 6pl2-21 respectively by PCR-LOH. From the use of these eight 6p probes in all the tumours, we selected seven tumours for a more extensive analysis with three further dinucleotide repeats mapping to the region 6pl2-6p23. We also included 12 nonmalignant ovarian tissue specimens in our RFLP analysis. Although not all these samples were analysed with all 18 probes, probes at 6p2l, 6q21 and 6qter were employed. In addition, we used probes mapping to chromosome 10p, 10q and 16q to study all of the malignant tumours to ensure that the losses seen were not random.
Materials and methods

Materials
Tumours were collected from consenting patients undergoing surgery for ovarian cancer. Lymphocytes were extracted from blood taken at the time or within a few days of the operation. These patients were unselected and were operated on at a number of hospitals in and around London. Figure 1 . The frozen sections allowed us to select the most tumour-rich part of the specimen for further analysis. Class- Table I Grading of tumours. This grading system is based on the WHO international classification of tumours (Serov et al., 1973) , with modifications adapted from Russell (1987) and Anderson (1991) (Serov et al., 1973) , with modifications based on Russell (1987) and Anderson (1991) . This method of classification is reproducible and the criteria are set out in Table I,  and Table II III  NA  III  III  III  III   II   III  III  NA  IV  II  III  III  IV   III   II   II   III   II aFor the grading system, see Table I . bThe percentage tumour in the sample used to make the DNA was estimated from frozen sections as described in Materials and methods. cStaging based on FIGO classification, NA: not available.
.1 (DIOS25) (lOq26) and p79-2-23 (D16S7) (16q24). The assignments for pCGa, pOR3 and pJCZ30 were based on Boyle et al. (1992) , who also found that the minisatellite probes pJCZ30, pYNZ132 and pMCOB12 (D6S37, D6S44 and D6S48 respectively) produced virtually identical bands on Southern blots and as our own data (Markie et al., 1992) showed that the probes pJCZ30 and MCOB12 have an identical restriction pattern, we decided to use pJCZ30 only for this study. The positions of TCPIO and D6S86 has been inferred from linkage data (Blanche et al., 1992; Markie et al., 1992) . The 3.6 kb, 3.0 kb and 2.6 kb BamHI bands seen on genomic Southern blots with p308 (D6ZI), have been mapped to the centromere by genetic means (Blanche et al., 1991 Table I ), repeated hybridisation of the filter with control chromosome probes and where there was doubt, densitometry was carried out using a LKB Ultrascan XL Laser Densitometer.
Dinucleotide repeat analysis Primers flanking highly polymorphic dinucleotide repeats at the D6S202, D6S89, D6S109, D6S105 and FTHPI loci were used in PCR of DNA from the normal-tumour matched samples described above. The PCR conditions used were as previously described (Litt & Luty, 1990 Radioactive samples (1-3;gl) were located onto 10% nondenaturing 0.4 mm polyacrylamide gels and exposed to Kodak XAR-5 film at room temperature for between 20 and 72 h.
Results
LOH on chromosome 6q
Where possible, all ten probes were used to study the 29 malignant tumours. The results are set out in Figure 2 , and representative autoradiographs are shown in Figure 3 . We have demonstrated that LOH of 6q probes is a common occurrence, with 16/29 (55%) showing LOH of one or more probes. As shown in Table III column 5, in those 16 tumours with 6q LOH, the loss involved all informative markers in 10 (63%). However, Tumour 9 had LOH limited to probes mapping distal to 6q24. This suggests that any tumour suppressor genes relevant to OC on the long arm of chromosome 6 will be distal to MYB. Table III ). This is not significantly different from the loss seen on chromosomes 10 and 16 and therefore may not in itself suggest the presence of a tumour suppressor gene on 6p, but two separate regions were involved, one between 6p22.3-pter (tumours 7, 10, 11, 42 and 64) and another at 6pl2 -6p22 (tumours 7, 9, 10 and 42), which includes the major histocompatability complex (MHC) mapping within 6p2l.3. LOH on 6p was always accompanied by LOH on 6q, but in only 50/o of cases was the reverse case ( Figure 2 and Table III (Figure 3) shows virtually complete LOH at both telomeres, but there is evidence from the DQa hybridisation that a significant proportion of the tumour cells in this sample have retained both alleles in this region. There was also retention seen in 6p22.3-23 with D6S89 (Figure 4) . Overall, our data show that there is independent LOH on both chromosome arms, as well as complex events within the retained sections.
LOH on chromosome 6 and histopathological grade Figure 5 illustrates 6q LOH in terms of pathological grade and histological subtypes. The grade 1 tumours contained between 45 and 75% tumour, and since we have noted LOH in some tumours where the proportion of tumour to stroma is less than this (for example tumour 61, Figures 1 and 2) , the absence of loss is probably a true negative. On 6p, LOH occurred in eight cases only; of these tumours, six were grade 3, and there was one tumour each in grades 2 and 2-3. Whilst the numbes for 6p and 6q are small and do not allow statistical analysis, they suggest that chromosome 6 LOH is commoner in higher grade OCs. With regard to histological subtype. mechanisms by which LOH can occur, amongst the commonest being non-disjunction with or without reduplication (Cavenee et al., 1983) . In this case all informative markers on the chromosome would show reduction to homozygosity, with one or two copies of the retained chromosome, depending on whether or not reduplication occurred. As only two out of eight cases with loss on 6p and q showed LOH of all informative markers, non-disjunction is not the commonest mechanism by which LOH occurs on chromosome 6 in OC. Therefore mechanisms other than non-disjunction, such as somatic recombination or deletion, must account for LOH on chromosome 6 in OC. Three tumours (9, 10 and 42) have interstitial deletions on 6p, which always include the MHC. In addition to these deletions, these tumours have LOH of 6q (Figures 2 and 4) . In the 16 cases with LOH on 6q, eight had LOH on 6p (Table III , column 4). However, 6p LOH was always accompanied by LOH on 6q. This may imply some disrupting effect of LOH on 6q on 6p or could be due to chance.
Combining our findings with all the published data on LOH of chromosome 6 in OC we can conclude that there is at least one tumour suppressor gene between 6q24-qter and based on three tumours in the studies of Dubeau and colleagues (Ehlen & Dubeau, 1990; Zheng et al., 1991) , the gene may be at 6q27. This gene is not restricted to any particular histopathological type. There is probably at least one tumour suppressor gene on 6p, both from our data and from that of Sato et al. (1991) . In their series of 37 tumours, this group found that three out of the four tumours that had LOH on 6p and not 6q were non-serous tumours. However, we did not find that 6p LOH was limited to nonserous tumours. Loss of MHC loci, which may give a tumour a selective advantage by escaping rejection by the immune system, might explain the LOH at 6pl2-6p22 seen in our study, but cannot account for the LOH seen at 6p22.3-pter. Thus other genes on 6p are likely to be implicated in OC.
There appears to be a difference in LOH seen on chromosome 6p and q in Japanese and Caucasian populations. Sato et al. (1991) found LOH on 6p in 6/12 cases using D6S29, which maps just proximal to the MHC (Zoghbi et al., 1990) , but on 6q only 5/29 cases showed LOH. Studies of caucasians give a different picture, with overall >50% LOH on 6q and much less LOH on 6p (0/9, Lee et al., 1990; 8/29 , this study). It is not clear whether this is related to genetic differences in the groups of women studied or is due to technical differences between laboratories, which will disappear as more tumours are studied.
Our data indicated that 6q LOH is more common in grade 3 tumours than in any other grade. Whether this implies that 6q LOH is a late event, or alternatively, that homozygous loss of a 6q gene leads to a more aggressive tumour is not known as there is debate about the origin, development and subsequent course of an ovarian tumour in vivo (Anderson, 1990, ppl87-190; Fox, 1990a, ppl65-167; Fox, 1990b, ppl85-186) . We have not seen any LOH on 6p or 6q in benign tumours. However, Russell et al. (1990) noted LOH on chromosome 17q in one benign ovarian tumour. We have demonstrated that LOH is more likely to occur in serous and undifferentiated adenocarcinomas than in the mucinous type, but interpretation of these results should be cautious, as three of the four mucinous tumours are grade 1 and therefore the true reason for the absence of LOH may be the low grade rather than the histological subtype. There is evidence from one paper that LOH of chromosome 6q is an early event in the course of OC (Zheng et al., 1991) , but larger studies will be needed to resolve this issue.
From several LOH studies, chromosome 6q appears to be involved in the pathogenesis of other solid tumours. These studies are summarised in Table IV . In addition to LOH data, deletions of 6q25-qter have been reported from cytogenetic studies of salivary gland adenocarcinoma (Stenman et al., 1989) . When considering all the published data, it is quite possible that a single gene at 6q27 could have relevance to the development and progression of a wide variety of tumour types. (McGuire et al., 1992) and an Ala-Val substitution was recognised by an RNase protection assay (Garcia et al., 1989) . Some of these variants have functional significance, acting in some cases as a dominant positive receptor, i.e. active in the absence of oestrogen, and in others as dominant negative: inactive but inhibiting the function of the normal receptor (McGuire et al., 1992) .
These studies, together with the possible linkage of lateonset breast cancer in one family to the ESR gene by Zuppan et al. (1991) and the high frequency of LOH in 6q in breast cancer (Devilee et al., 1991) , 52, 5815-5817, 1992) have recently reported 52% LOH on chromosome 6q in serous adenocarcinomas of the ovary. These findings extend their previous work and suggest that the minimum deleted region in serous adenocarcinomas is a 1.9cM region within 6q27. This result is consistent with our own findings. It therefore appears that the differences between Japanese and caucasian ovarian carcinomas is less than might have been suspected from the original publications.
